Selecting a Treatment Regimen Table 1. Recommendations for the Treatment of MRSA Treatments Manifestation
Management/ Surgery
Duration of Therapy Agent Skin and Soft Tissue Infections (SSTI)* - Outpatients (continued)
Clindamycin (Cleocin® others)
, Purulent cellulitis
(cellulitis associated with purulent drainage or exudate in the absence of a drainable abscess)
Empiric therapy for CA-MRSA (A-II).
No therapy for β-hemolytic streptococci (A-II).
Treat for 5-10 days.†
TMP-SMX‡ (Bactrim®
)
300-450 mg PO tid
1-2 DS tab PO bid
Doxycycline 100 mg PO bid
Minocycline (Minocin®
)
Linezolid (Zyvox®
)
β-lactam (eg, cephalexin,‡ dicloxacillin)
Non-purulent cellulitis
(cellulitis with no purulent drainage or exudate and no associated abscess)
Empiric therapy for β-hemolytic streptococci (A-II) and for CA-MRSA in patients who fail to respond to β-lactam therapy or those with systemic toxicity.
Treat for 5-10 days.†
β-lactam (eg, amoxicillin‡
500 mg PO qid
200 mg x 1, then 100 mg PO/IV bid
600 mg PO bid
Antibiotics Adult Dose
)
and TMP-SMX‡ (Bactrim®
Linezolid (Zyvox®
)
Clindamycin (Cleocin® others)
,
300-450 mg PO tid
NOTE: The use of rifampin as a single agent or as adjunctive therapy for the treatment of SSTI is NOT recommended (A-III).
) or a tetracycline 600 mg PO bid
Amox: 500 mg PO tid See above for TMP-SMX‡ and tetracycline dosing
2
(cont'd)
(Br
and)
